SCHEMBL4887008

SCHEMBL4887008

c1csc(-c2cc[se]c2-c2cccs2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.38
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
LTA4H P09960 3/20 0.37
HSD17B10 Q99714 4/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ATM Q13315 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
LTK P29376 1/20 0.35
CDK5 Q00535 1/20 0.35
MST1R Q04912 1/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531098 0.70 ALOX5 (0.35) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL6280818 0.69 KDM4E (0.48) TDO2KDM4EALDH1A1MAPTHPGD
SCHEMBL995326 0.69 LTA4H (0.55) TDO2KDM4EALDH1A1MAPTHPGD
SCHEMBL16291133 0.68 L3MBTL1 (0.57) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL3545 0.68 L3MBTL1 (0.57) KDM4EALDH1A1MAPTHPGDMEN1
Hydrogen Sulfide SCHEMBL752785 0.67 LTA4H (0.53) TDO2KDM4EALDH1A1MAPTHPGD
SCHEMBL29945128 0.66 LTA4H (0.47) TDO2KDM4EALDH1A1MAPTHPGD
SCHEMBL22734783 0.66 KDM4E (0.44) TDO2KDM4EALDH1A1MAPTHPGD
SCHEMBL7212806 0.66 KDM4E (0.50) TDO2KDM4EALDH1A1MAPTHPGD
SCHEMBL9927346 0.66 LTA4H (0.47) TDO2KDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103732721-A Luminescent solar concentrator comprising disubstituted benzoselenadiazole compounds ENI SPA 2014-04-16 CN claimed
CN-103732721-A Luminescent solar concentrator comprising disubstituted benzoselenadiazole compounds ENI SPA 2014-04-16 CN disclosed
US-20080303000-A1 Monomers, Oligomers and Polymers Comprising Thiophene and Selenophene MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
EP-1021178-A4 SELENOPHENE ANTI-TUMOR AGENTS PURDUE RESEARCH FOUNDATION (US) 2002-04-10 EP disclosed
EP-1021178-A1 SELENOPHENE ANTI-TUMOR AGENTS PURDUE RESEARCH FOUNDATION (US) 2000-07-26 EP disclosed
WO-1997046225-A1 SELENOPHENE ANTI-TUMOR AGENTS PURDUE RESEARCH FOUNDATION (US) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080303000-A1 Monomers, Oligomers and Polymers Comprising Thiophene and Selenophene SELENOI, SELE, SLCO2A1 TDO2 581/4885KDM4E 3601/4885ALDH1A1 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.